Kevin Kunzmann

The Medtronic MiniMed 670G system was expanded for pediatric T1D patients, then reported positive real-world symptom management during ADA 2018.

Though the rate of suicidal ideation in pediatric patients with T1D is not significant from general population, girls reported twice as frequent rates.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The investigative GLP-1 receptor agonist was compared to liraglutide, sitagliptin, and placebo in adult patients with type 2 diabetes.

Students battle stigma, uncertainty, and hurricanes to return home with an MD. But is it as bad as advertised?

Researchers found nonfatal opioid overdose survivors have a 20-fold greater mortality rate in the months following their incident. However, designated therapies for such patients have been proven to counter that risk.

The software is now indicated to assist physicians treating patients with T1D who use insulin pumps and continuous glucose monitoring.

The fixed-dose combination therapy from Valeant Pharmaceuticals International is vying to become the first and only approved topical lotion for the condition.

The 1300-plus patient survey interim results show patients struggle with fatigue and maintaining control of daily functions.

A national discussion on a public health crisis is slowing down before it can even really start — again.

The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee panel voted 11-4 to support the benefits of the INCRAFT AAA Stent Graft System from Cardinal Health.

Children with conditions such as ADHD could be put at greater risk of obesity or type 2 diabetes due to antipsychotic prescriptions.

The therapy's currently-planned phase 3 trials for major depressive disorder, postpartum depression disorder are being converted into pivotal studies after a meeting with the FDA.

Children with autism are nearly twice as likely to have any allergic condition than those without autism, researchers found.

The rare condition affects 30,000-40,000 US patients annually. Rituximab becomes its first indicated biologic treatment.

The CDC reported that suicide rates have increased by at least 30% in half of all US states.

The prevalence of HDP and neurodevelopmental disorders are associated with increased risks up to 70%, according to the systematic review and meta-analysis.

The therapy, currently approved in oral and injectable formulations, is being considered for adult women with symptoms.

The therapy, when combined with oral antidepressant, reported a 70% reduction in relapse risk for depression versus standard-of-care.

This week, the FDA approved the first standalone prosthetic iris, granted priority review to a pediatric anti-epileptic and a postpartum depression drug, accepted another try from an opioid use disorder drug, and announced new plans against the opioid epidemic.

The fluticasone propionate nasal spray is indicated for treatment of seasonal and perennial allergic rhinitis, as well as the management of sinus pain and pressure associated with pediatric rhinitis.

The new findings also show that the premature activation of synapses can be prevented by AMPA receptor antagonist therapy.

The CustomFlex Artificial Iris is customizable by both size and eye color, and indicated for both adults and children.

The NeuralBot assists clinicians in non-invasive monitor of patient brain blood flow characteristics, and provides diagnostic information for a variety of neurological disorders.

The investigative monoclonal antibody has more data backing its efficacy, safety, and tolerability across 2 dose regimens.